SG10201805584YA - ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB - Google Patents

ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB

Info

Publication number
SG10201805584YA
SG10201805584YA SG10201805584YA SG10201805584YA SG10201805584YA SG 10201805584Y A SG10201805584Y A SG 10201805584YA SG 10201805584Y A SG10201805584Y A SG 10201805584YA SG 10201805584Y A SG10201805584Y A SG 10201805584YA SG 10201805584Y A SG10201805584Y A SG 10201805584YA
Authority
SG
Singapore
Prior art keywords
antigen
binding
molecule
binding molecule
binding domain
Prior art date
Application number
SG10201805584YA
Inventor
Tomoyuki Igawa
Atsuhiko Maeda
Yuki Iwayanagi
Kenta Haraya
Hitoshi Katada
Shojiro Kadono
Futa Mimoto
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2012/054624 external-priority patent/WO2012115241A1/en
Priority claimed from PCT/JP2012/075092 external-priority patent/WO2013047752A1/en
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of SG10201805584YA publication Critical patent/SG10201805584YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA Fc g RIIB 5 The present invention provides antigen-binding molecules containing (i) an antigen-binding domain whose antigen-binding activity varies depending on ion concentration conditions, (ii) an Fc g -binding domain having Fc g RIIb-selective binding activity, and (iii) an FcRn-binding domain having FcRn-binding activity under an acidic pH range condition, and methods of decreasing plasma antigen concentration as compared to before administering the molecule, 10 which include the step of administering the molecule. No Fig.
SG10201805584YA 2012-02-24 2013-02-22 ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB SG10201805584YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/JP2012/054624 WO2012115241A1 (en) 2011-02-25 2012-02-24 Fcγriib-specific fc antibody
JP2012185866 2012-08-24
PCT/JP2012/075092 WO2013047752A1 (en) 2011-09-30 2012-09-28 Antigen-binding molecule for promoting loss of antigens

Publications (1)

Publication Number Publication Date
SG10201805584YA true SG10201805584YA (en) 2018-08-30

Family

ID=49005844

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201405137QA SG11201405137QA (en) 2012-02-24 2013-02-22 ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB
SG10201805584YA SG10201805584YA (en) 2012-02-24 2013-02-22 ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201405137QA SG11201405137QA (en) 2012-02-24 2013-02-22 ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB

Country Status (16)

Country Link
US (2) US20160046693A1 (en)
EP (2) EP3738980A1 (en)
JP (5) JP6138108B2 (en)
KR (3) KR102219987B1 (en)
CN (2) CN104244980B (en)
AU (3) AU2013223087B2 (en)
BR (1) BR112014020821B1 (en)
CA (1) CA2865158C (en)
DK (1) DK2818183T3 (en)
ES (1) ES2795419T3 (en)
HK (1) HK1201476A1 (en)
MX (2) MX370668B (en)
RU (1) RU2736349C2 (en)
SG (2) SG11201405137QA (en)
TW (4) TWI617577B (en)
WO (1) WO2013125667A1 (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3056568T3 (en) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd PROCEDURES FOR CONTROL OF THE BLOOD PHARMACOKINETICS OF ANTIBODIES
JP5334319B2 (en) 2007-09-26 2013-11-06 中外製薬株式会社 Method for modifying isoelectric point of antibody by amino acid substitution of CDR
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2806252C (en) 2010-07-29 2019-05-14 Xencor, Inc. Antibodies with modified isoelectric points
SG10201509790YA (en) 2010-11-30 2015-12-30 Chugai Pharmaceutical Co Ltd Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly
MX352889B (en) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Fcî“riib-specific fc antibody.
TWI687441B (en) 2011-06-30 2020-03-11 中外製藥股份有限公司 Heterodimerized polypeptide
TW201326209A (en) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
EP3939996A1 (en) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
SG10201609301QA (en) 2011-11-30 2016-12-29 Chugai Pharmaceutical Co Ltd Drug containing carrier into cell for forming immune complex
US20150353630A1 (en) * 2012-05-30 2015-12-10 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
EP3795215A1 (en) 2012-05-30 2021-03-24 Chugai Seiyaku Kabushiki Kaisha Target tissue-specific antigen-binding molecule
JP6501521B2 (en) 2012-08-24 2019-04-17 中外製薬株式会社 FcγRIIb-specific Fc region variant
EP3597747B1 (en) 2012-08-24 2023-03-15 Chugai Seiyaku Kabushiki Kaisha Mouse fcgammarii-specific fc antibody
KR102249779B1 (en) 2012-12-27 2021-05-07 추가이 세이야쿠 가부시키가이샤 Heterodimerized polypeptide
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
AU2014205086B2 (en) 2013-01-14 2019-04-18 Xencor, Inc. Novel heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
CA2897987A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
JP6534615B2 (en) 2013-09-27 2019-06-26 中外製薬株式会社 Method for producing polypeptide heteromultimer
TWI664331B (en) 2013-12-04 2019-07-01 日商中外製藥股份有限公司 Antigen-binding molecules that change antigen-binding ability in response to compound concentration and its database
RS59907B1 (en) 2014-03-28 2020-03-31 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
EP3194449A1 (en) 2014-07-24 2017-07-26 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
KR20170084327A (en) 2014-11-26 2017-07-19 젠코어 인코포레이티드 Heterodimeric antibodies that bind cd3 and cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CN116333153A (en) 2014-11-26 2023-06-27 森科股份有限公司 Heterodimeric antibodies that bind CD3 and tumor antigens
TWI779010B (en) 2014-12-19 2022-10-01 日商中外製藥股份有限公司 ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT Fc REGIONs, AND METHODS OF USE
PT3233921T (en) 2014-12-19 2021-12-09 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
US9969800B2 (en) 2015-02-05 2018-05-15 Chugai Seiyaku Kabushiki Kaisha IL-8 antibodies
AU2016224409B2 (en) 2015-02-27 2021-01-28 Chugai Seiyaku Kabushiki Kaisha Composition for treating IL-6-related diseases
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
JP6266164B2 (en) 2015-09-18 2018-01-31 中外製薬株式会社 Antibodies that bind to IL-8 and uses thereof
US11623957B2 (en) 2015-12-07 2023-04-11 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
US20190263918A1 (en) * 2016-06-08 2019-08-29 Shanghai Jiao Tong University School Of Medicine Sequence of antibody heavy chain constant region for enhancing agonistic antibody activity
RU2767357C2 (en) 2016-06-14 2022-03-17 Ксенкор, Инк. Bispecific checkpoint inhibitors antibodies
CA3019904A1 (en) 2016-06-17 2017-12-21 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3475304B1 (en) 2016-06-28 2022-03-23 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
SG11201900616UA (en) 2016-08-02 2019-02-27 Visterra Inc Engineered polypeptides and uses thereof
SG11201801024XA (en) 2016-08-05 2018-05-30 Chugai Pharmaceutical Co Ltd Therapeutic or preventive compositions for il-8-related diseases
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
US10550185B2 (en) 2016-10-14 2020-02-04 Xencor, Inc. Bispecific heterodimeric fusion proteins containing IL-15-IL-15Rα Fc-fusion proteins and PD-1 antibody fragments
US11608374B2 (en) 2017-01-30 2023-03-21 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
AU2018255938A1 (en) 2017-04-21 2019-10-31 Staten Biotechnology B.V. Anti-ApoC3 antibodies and methods of use thereof
WO2018203545A1 (en) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Method for predicting and evaluating therapeutic effect in diseases related to il-6 and neutrophils
WO2019006472A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
KR101987268B1 (en) * 2017-10-12 2019-06-10 국민대학교 산학협력단 Fc gamma receptor variant, MG2A45
CN107621548A (en) * 2017-09-15 2018-01-23 深圳市因诺赛生物科技有限公司 Sequestered and the total IgE measure diagnostic kits of cell mating type and preparation method in people's whole blood
KR101987279B1 (en) * 2017-10-12 2019-06-10 국민대학교 산학협력단 Fc gamma receptor variant, MG2A45.1
KR101987272B1 (en) * 2017-09-15 2019-06-10 국민대학교 산학협력단 Fc gamma receptor variant MG2A28.1
KR101986252B1 (en) * 2017-09-15 2019-06-05 국민대학교 산학협력단 Fc gamma receptor variant MG2A28
KR101987292B1 (en) * 2017-10-12 2019-06-10 국민대학교 산학협력단 Fc gamma receptor variant, MG2B45.1
CA3080103A1 (en) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
CA3082383A1 (en) 2017-11-08 2019-05-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN111655718A (en) 2017-12-19 2020-09-11 Xencor股份有限公司 Engineered IL-2 FC fusion proteins
CN116327926A (en) 2018-03-15 2023-06-27 中外制药株式会社 Anti-dengue virus antibodies with cross-reactivity to Zika virus and methods of use
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
WO2019204655A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
JP2021521784A (en) 2018-04-18 2021-08-30 ゼンコア インコーポレイテッド PD-1 targeted heterodimer fusion proteins containing IL-15 / IL-15RaFc fusion proteins and PD-1 antigen binding domains and their use
SG10202106830VA (en) 2018-08-10 2021-08-30 Chugai Pharmaceutical Co Ltd Anti-cd137 antigen-binding molecule and utilization thereof
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
KR20210134725A (en) 2019-03-01 2021-11-10 젠코어 인코포레이티드 Heterodimeric Antibodies that Bind to ENPP3 and CD3
US20220153875A1 (en) 2019-03-19 2022-05-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain
CN114867532A (en) 2019-12-18 2022-08-05 豪夫迈·罗氏有限公司 Bispecific anti-CCL 2 antibodies
TW202144395A (en) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 Anti-CD137 antigen-binding molecule for use in cancer treatment
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
IL305736A (en) 2021-03-09 2023-11-01 Xencor Inc Heterodimeric antibodies that bind cd3 and cldn6
EP4305065A1 (en) 2021-03-10 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
WO2022263501A1 (en) 2021-06-18 2022-12-22 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
CN117616123A (en) * 2021-06-25 2024-02-27 中外制药株式会社 anti-CTLA-4 antibodies

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE275198T1 (en) 1991-12-02 2004-09-15 Medical Res Council PRODUCTION OF ANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES.
JPH07503132A (en) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド Transgenic non-human animals capable of producing xenoantibodies
JP3507073B2 (en) 1992-03-24 2004-03-15 ケンブリッジ アンティボディー テクノロジー リミティド Methods for producing members of a specific binding pair
ATE381614T1 (en) 1992-07-24 2008-01-15 Amgen Fremont Inc FORMATION OF XENOGENE ANTIBODIES
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
FR2707189B1 (en) 1993-07-09 1995-10-13 Gradient Ass Method for treating combustion residues and installation for implementing said method.
AU690171B2 (en) 1993-12-03 1998-04-23 Medical Research Council Recombinant binding proteins and peptides
ATE340590T1 (en) 1994-07-13 2006-10-15 Chugai Pharmaceutical Co Ltd RECONSTITUTED HUMAN ANTIBODY DIRECTED AGAINST HUMAN INTERLEUKIN-8
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP1709970A1 (en) 1995-04-27 2006-10-11 Abgenix, Inc. Human antibodies against EGFR, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69731289D1 (en) 1996-03-18 2004-11-25 Univ Texas IMMUNGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-VALUE TIMES
EP2364997A3 (en) 1999-01-15 2012-07-04 Genentech, Inc. Polypeptide variants with altered effector function
DK1332209T3 (en) 2000-09-08 2010-03-29 Univ Zuerich Collections of repeat proteins containing repeat modules
WO2002032925A2 (en) 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
ES2727425T3 (en) 2000-12-12 2019-10-16 Medimmune Llc Molecules with prolonged half-lives, compositions and uses thereof
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
JP4281869B2 (en) 2001-06-22 2009-06-17 中外製薬株式会社 Cell growth inhibitor containing anti-glypican 3 antibody
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7750204B2 (en) 2002-06-05 2010-07-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing antibody
WO2004022595A1 (en) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
AU2003286467B2 (en) 2002-10-15 2009-10-01 Abbvie Biotherapeutics Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
CA2545539A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
AU2004284090A1 (en) 2003-10-24 2005-05-06 Avidia, Inc. LDL receptor class A and EGF domain monomers and multimers
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
SG173322A1 (en) * 2004-04-16 2011-08-29 Macrogenics Inc Dw Us Fc gammad riib - specific antibodies and methods of use thereof
KR101413402B1 (en) 2004-07-09 2014-06-27 츄가이 세이야꾸 가부시키가이샤 Anti-Glypican 3 Antibody
AU2005272993B2 (en) * 2004-07-15 2010-02-11 Xencor, Inc Optimized Fc variants
DK1776384T3 (en) * 2004-08-04 2013-09-02 Mentrik Biotech Llc VARIANT Fc REGIONS
EP1778728A2 (en) 2004-08-19 2007-05-02 Genentech, Inc. Polypeptide variants with altered effector function
EP1812068A4 (en) 2004-10-29 2010-06-09 Medimmune Inc Methods of preventing and treating rsv infections and related conditions
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006053301A2 (en) 2004-11-12 2006-05-18 Xencor, Inc. Fc variants with altered binding to fcrn
WO2006067847A1 (en) 2004-12-22 2006-06-29 Chugai Seiyaku Kabushiki Kaisha Method of preparing antibody by use of cell having its fucose transporter function inhibited
CA2602663A1 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc variants with optimized properties
KR101374454B1 (en) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 Methods for producing polypeptides by regulating polypeptide association
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
DK2049564T3 (en) 2006-08-02 2017-07-24 Uab Res Found METHODS AND COMPOSITIONS RELATED TO SOLUBLE MONOCLONAL VARIABLE Lymphocyte RECEPTORS WITH DEFINED ANTIGEN SPECIFICITY
RS53263B (en) 2006-08-14 2014-08-29 Xencor Inc. Optimized antibodies that target cd19
EA017611B1 (en) 2007-01-05 2013-01-30 Юнивэсэти Оф Цюрих Method for preparing a disorder-associated protein specific binding molecule or an antibody or a binding fragment or at least one immunoglobulin chain, binding said protein (variants), a binding molecule, an antibody, an immunoglobulin chain or a binding fragment thereof (variants), an antigen, a polynucleotide, vector and a host-cell, a composition comprising them and a kit and a method of diagnosing or treating neurological disorders by using said subjects (variants)
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
DK2176298T3 (en) 2007-05-30 2018-02-12 Xencor Inc Methods and compositions for inhibiting CD32B-expressing cells
SI2808343T1 (en) 2007-12-26 2019-10-30 Xencor Inc Fc variants with altered binding to FcRn
WO2009095235A1 (en) * 2008-01-29 2009-08-06 Ablynx N.V. Methods to stabilize proteins and polypeptides
CA2721052C (en) * 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
BR122021026834B1 (en) * 2008-04-25 2022-11-08 Takeda Pharmaceutical Company Limited ISOLATED ANTIBODIES BINDING FCRN, PHARMACEUTICAL COMPOSITION COMPRISING THEMSELVES AND METHODS TO DETECT AND MODULATE FCRN
KR102100066B1 (en) 2008-10-14 2020-04-10 제넨테크, 인크. Immunoglobulin variants and uses thereof
EP2391384A4 (en) 2009-01-29 2012-12-26 Medimmune Llc Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
TWI544077B (en) * 2009-03-19 2016-08-01 Chugai Pharmaceutical Co Ltd Antibody constant region change body
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
TWI667346B (en) * 2010-03-30 2019-08-01 中外製藥股份有限公司 Antibodies with modified affinity to fcrn that promote antigen clearance
SG10201509790YA (en) * 2010-11-30 2015-12-30 Chugai Pharmaceutical Co Ltd Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly
WO2012132067A1 (en) * 2011-03-30 2012-10-04 中外製薬株式会社 Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
MX352889B (en) * 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Fcî“riib-specific fc antibody.
AU2012233313C1 (en) * 2011-03-30 2017-08-03 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
TWI580693B (en) * 2011-09-30 2017-05-01 中外製藥股份有限公司 Antigen-binding molecule that promotes the disappearance of antigen
EP3939996A1 (en) * 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
JP6352634B2 (en) * 2011-09-30 2018-07-04 中外製薬株式会社 Antigen-binding molecules that induce immune responses to target antigens
JP6501521B2 (en) * 2012-08-24 2019-04-17 中外製薬株式会社 FcγRIIb-specific Fc region variant
WO2014133515A1 (en) * 2013-02-28 2014-09-04 Hewlett-Packard Development Company, L.P. Arranging elements in a layout

Also Published As

Publication number Publication date
KR102219987B1 (en) 2021-02-25
EP2818183A1 (en) 2014-12-31
AU2013223087B2 (en) 2018-02-22
TWI617577B (en) 2018-03-11
CA2865158A1 (en) 2013-08-29
WO2013125667A1 (en) 2013-08-29
JP2017197536A (en) 2017-11-02
US20230140797A1 (en) 2023-05-04
JPWO2013125667A1 (en) 2015-07-30
ES2795419T3 (en) 2020-11-23
KR20140130707A (en) 2014-11-11
JP6138108B2 (en) 2017-05-31
RU2736349C2 (en) 2020-11-16
JP2024038068A (en) 2024-03-19
SG11201405137QA (en) 2014-12-30
EP3738980A1 (en) 2020-11-18
CN104244980B (en) 2017-11-10
CN107266564A (en) 2017-10-20
KR20220136441A (en) 2022-10-07
JP7411698B2 (en) 2024-01-11
JP2022043347A (en) 2022-03-15
TW201343673A (en) 2013-11-01
CN104244980A (en) 2014-12-24
AU2018202968A1 (en) 2018-05-17
TW202231872A (en) 2022-08-16
BR112014020821B1 (en) 2022-11-16
KR20210022764A (en) 2021-03-03
EP2818183B1 (en) 2020-04-01
TW201900681A (en) 2019-01-01
JP2020073557A (en) 2020-05-14
MX370668B (en) 2019-12-19
EP2818183A4 (en) 2015-11-04
US20160046693A1 (en) 2016-02-18
JP6669688B2 (en) 2020-03-18
CA2865158C (en) 2022-11-01
JP7012104B2 (en) 2022-02-10
HK1201476A1 (en) 2015-09-04
TWI682939B (en) 2020-01-21
TW202015731A (en) 2020-05-01
BR112014020821A2 (en) 2017-07-04
MX2018013128A (en) 2023-04-28
AU2018202643A1 (en) 2018-05-10
KR102475951B1 (en) 2022-12-08
AU2018202968B2 (en) 2020-04-23
AU2013223087A1 (en) 2014-09-18
RU2014138499A (en) 2016-04-20
MX2014010140A (en) 2014-09-12
DK2818183T3 (en) 2020-06-15

Similar Documents

Publication Publication Date Title
SG10201805584YA (en) ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB
MX2021008816A (en) Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof.
MX2014014678A (en) Target-tissue-specific antigen-binding molecule.
AU2016204248A1 (en) Boron-Containing Molecules
WO2012034116A3 (en) Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
EA201490029A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
EA202193044A2 (en) METHODS OF TREATMENT OF TAUPATHY
EA201491151A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
SG195073A1 (en) Deimmunized serum-binding domains and their use for extending serum half-life
MX365864B (en) Novel bicyclic bromodomain inhibitors.
WO2013184912A3 (en) Binding agents that modulate the hippo pathway and uses thereof
EA201591746A1 (en) METHODS AND COMPOSITIONS FOR INHIBITING BRODOMODEN-CONTAINING PROTEINS
EA201690007A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
IN2014DN00286A (en)
IN2014MN00093A (en)
BR112013020500A8 (en) isolated, recombinant or purified antibody
EA201391332A1 (en) OPIOID RECEPTOR LIGANDS AND METHODS OF THEIR APPLICATION AND RECEIVING
AU2012249274A8 (en) Neutralizing antibodies to Nipah and Hendra virus
SG10201804385YA (en) Stimulus responsive polymers for the purification of biomolecules
EA201490778A1 (en) ANTIBODIES AGAINST HtrA1 AND METHODS OF APPLICATION
IN2014DN08481A (en)
EA201390704A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
EA201300127A1 (en) COMBINED PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF THE HEAD DIFFERENCE OF DIFFERENT GENESIS, KINETOSIS AND VEGETOSYVASCULAR DYSTONIA
WO2013028334A3 (en) Use of small molecules in methods for purification of biomolecules
IN2014CN03062A (en)